Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2015

01-11-2015 | Correspondence

GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment

Authors: P. J. Vlachostergios, R. L. Balmiki, R. Daya

Published in: Clinical and Translational Oncology | Issue 11/2015

Login to get access

Excerpt

We read with great interest the study of Mandelin et al. which constitutes a substantial breakthrough in the exploitation of phage display technology for investigation of a unique osteoblastic prostate castrate-resistant cancer model [1]. More importantly, the two peptides identified in this study, PKRGFQD and SNTRVAP, together with their respective receptors, α2-macroglobulin, and glucose-regulated protein 78 (GRP78) were found to be enriched in the tumors and are suggested as potentially drug able targets for metastatic androgen-independent prostate cancer (PC) [1]. …
Literature
1.
Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, et al. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci USA. 2015. (pii: 201500128).
2.
Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, et al. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate. 2013;73:932–40.PubMedCentralCrossRefPubMed
3.
Asplin IR, Wu SM, Mathew S, Bhattacharjee G, Pizzo SV. Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis. Blood. 2001;97:3450–7.CrossRefPubMed
4.
Booth L, Roberts JL, Tavallai M, Nourbakhsh A, Chuckalovcak J, Carter J, et al. OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood Brain Barrier: Implications for Anti-Cancer Therapies. J Cell Physiol. 2015. doi:10.​1002/​jcp.​24977.
5.
Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014;6:252ra122.
6.
Misra UK, Pizzo SV. Activated α2-Macroglobulin Binding to Human Prostate Cancer Cells Triggers Insulin-like Responses. J Biol Chem. 2015. (pii: jbc.M114.617837).
7.
Misra UK, Pizzo SV. Receptor-recognized α2-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells. PLoS ONE. 2012;7:e51735.PubMedCentralCrossRefPubMed
8.
Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, et al. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2015;13:113–23.CrossRefPubMed
9.
Pootrakul L, Datar RH, Shi SR, Cai J, Hawes D, Groshen SG, et al. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res. 2006;12:5987–93.CrossRefPubMed
10.
Misra UK, Payne S, Pizzo SV. Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen. J Biol Chem. 2011;286:1248–59.PubMedCentralCrossRefPubMed
11.
Tan SS, Ahmad I, Bennett HL, Singh L, Nixon C, Seywright M, et al. GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J Pathol. 2011;223:81–7.CrossRefPubMed
12.
Zhang Y, Tseng CC, Tsai YL, Fu X, Schiff R, Lee AS. Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3 K and enhances PI(3,4,5)P3 production. PLoS ONE. 2013;8:e80071.PubMedCentralCrossRefPubMed
13.
Tang Y, Wang L, Goloubeva O, Khan MA, Zhang B, Hussain A. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy. Clin Cancer Res. 2008;14:2936–43.CrossRefPubMed
14.
Vasileiou C, Hatzidaki E, Karkabounas A, Maragkouli E, Vaiou M, Dimas K, et al. Effect of ET-1, FGF-2, and HGF on intracellular steroidogenesis in prostate cancer cells. J Clin Oncol. 2013;31(suppl):abstr e16083.
15.
Gonzalez-Gronow M, Cuchacovich M, Llanos C, Urzua C, Gawdi G, Pizzo SV. Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res. 2006;66:11424–31.CrossRefPubMed
16.
Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, et al. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol. 2007;38:1547–52.CrossRefPubMed
17.
Bartkowiak K, Effenberger KE, Harder S, Andreas A, Buck F, Peter-Katalinic J, et al. Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. J Proteome Res. 2010;9:3158–68.CrossRefPubMed
18.
Pfaffenbach KT, Pong M, Morgan TE, Wang H, Ott K, Zhou B, et al. GRP78/BiP is a novel downstream target of IGF-1 receptor mediated signaling. J Cell Physiol. 2012;227:3803–11.PubMedCentralCrossRefPubMed
19.
Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, et al. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014;74:225–34.CrossRefPubMed
20.
Aggarwal RR, Ryan CJ, Chan JM. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Urol Oncol. 2013;31:522–30.CrossRefPubMed
21.
Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, et al. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol. 2014;66:468–74.CrossRefPubMed
22.
Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN Jr, et al. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014;33:4521–30.PubMedCentralCrossRefPubMed
23.
Abdel Malek MA, Jagannathan S, Malek E, Sayed DM, Elgammal SA, Abd El-Azeem HG, et al. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget. 2015;6:3098–110.PubMedCentralCrossRefPubMed
24.
Leclerc GM, Leclerc GJ, Kuznetsov JN, DeSalvo J, Barredo JC. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts. PLoS ONE. 2013;8:e74420.PubMedCentralCrossRefPubMed
25.
Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012;110:1729–35.CrossRefPubMed
26.
Misra UK, Pizzo SV. Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. Cancer Biol Ther. 2010;9:142–52.CrossRefPubMed
27.
Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra SK, et al. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3 K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res. 2013;19:6802–11.PubMedCentralCrossRefPubMed
28.
Maddalo D1, Neeb A, Jehle K, Schmitz K, Muhle-Goll C, Shatkina L, et al. A peptidic unconjugated GRP78/BiP ligand modulates the unfolded protein response and induces prostate cancer cell death. PLoS One. 2012 7:e45690.
29.
Roller C, Maddalo D. The Molecular Chaperone GRP78/BiP in the Development of Chemoresistance: Mechanism and Possible Treatment. Front Pharmacol. 2013;4:10.PubMedCentralCrossRefPubMed
30.
Delie F, Petignat P, Cohen M. GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78. Target Oncol. 2013;8:225–30.CrossRefPubMed
31.
Su SF, Chang YW, Andreu-Vieyra C, Fang JY, Yang Z, Han B, et al. miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene. 2013;32:4694–701.PubMedCentralCrossRefPubMed
32.
Wu Y, Fabritius M, Ip C. Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer. Cancer Biol Ther. 2009;8:146–52.PubMedCentralCrossRefPubMed
33.
Zu S, Ma W, Xiao P, Cui Y, Ma T, Zhou C, et al. Evaluation of Docetaxel-Sensitive and Docetaxel-Resistant Proteomes in PC-3 Cells. Urol Int. 2015 [Epub ahead of print].
34.
Lee E, Nichols P, Groshen S, Spicer D, Lee AS. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer. 2011;128:726–31.PubMedCentralCrossRefPubMed
Metadata
Title
GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment
Authors
P. J. Vlachostergios
R. L. Balmiki
R. Daya
Publication date
01-11-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1324-9

Other articles of this Issue 11/2015

Clinical and Translational Oncology 11/2015 Go to the issue

Research Article

miR-448 negatively regulates ovarian cancer cell growth and metastasis by targeting CXCL12

Research Article

Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice

Research Article

The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival

Research Article

Effectiveness and toxicity of helical tomotherapy for patients with locally recurrent nasopharyngeal carcinoma

Research Article

Hepatic arterial infusion plus systemic chemotherapy as third-line or later treatment in colorectal liver metastases

Retraction Note

Retraction Note to: Profiling of differentially expressed microRNAs (miRNAs) during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma (HCC) cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits